Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a...

Area of Science:

• Cardiology
• Pharmacology
• Physiology

Background:

• Severe chronic congestive heart failure (CHF) is linked to impaired left ventricular (LV) function and elevated cardiovascular hormones.
• Understanding the relationship between LV systolic function and neurohormone levels is crucial for managing CHF.

Purpose of the Study:

• To investigate the impact of enalapril on LV function and cardiovascular hormone levels in severe CHF patients.
• To determine the correlation between changes in neurohormone levels and improvements in LV function.

Main Methods:

• Randomized controlled trial comparing enalapril to placebo in severe CHF patients on conventional therapy.
• M-mode echocardiography and plasma hormone assays (angiotensin-II, norepinephrine, aldosterone) were performed at baseline and after 6 weeks.
• Systolic time interval index was also measured to assess LV performance.

Main Results:

• Enalapril significantly improved LV fractional shortening and decreased the systolic time interval index.
• Treatment with enalapril led to a significant reduction in angiotensin-converting enzyme activity, aldosterone, angiotensin-II, and norepinephrine levels.
• The placebo group showed no significant changes in LV function or hormone levels.
• No direct correlation was found between the magnitude of neurohormone reduction and the degree of LV function improvement.

Conclusions:

• Severe LV systolic dysfunction in CHF is associated with elevated angiotensin-II and norepinephrine, which enalapril can effectively reduce.
• Enalapril favorably modifies neurohormone profiles in severe CHF, potentially impacting long-term survival.
• Predicting LV function changes solely based on individual neurohormone levels is insufficient due to complex interactions.